Scinovia offering is now closed and is no longer accepting investments.

INVEST IN SCINOVIA TODAY!

Point-and-Image to Know-the-Flow

Scinovia’s mission is to produce state-of-the-art diagnostics to help doctors make more data-driven decisions during procedures to save more lives. Scinovia developed VUFLOW, the future of non-contact imaging diagnostics for blood flow during surgery.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Scinovia

$112,512.53 Raised

REASONS TO INVEST

Reasons Icon

Help save more lives with an FDA Class I Augmented Reality Surgical Camera

Reasons Icon

300 million surgeries per year and good blood flow is a key to recovery

Reasons Icon

Current measurement tools originated in the ‘60s and require contact or injection of a contrast dye.

OVERVIEW


MedTech imaging for non-contact visualization of blood flow

Scinovia Corp. is a medtech company engaged in the development of proprietary, non-contact diagnostics for cardiovascular and vascular surgeries with the aim to enhance patient outcomes, making surgeries safer and more cost-effective. We focus on improving outcomes of heart bypass, revascularization, and organ transplant therapies where blood flow is key to recovery and to reduce death and costly complications.


Scinovia is entering a growing market of $500M in sales last year with a revolutionary device VUFLOW that provides non-contact, real-time, quantitative data. Presently, the market relies on contact methods that were developed 60 years ago.


Our product roadmap includes a robotic-assisted diagnostic to enhance ease of use and precision while visualizing blood flow during surgery.

Scinovia is a pre-revenue, FDA registered company. VUFLOW units are being scheduled to enter hospitals in 2022 to explore diverse therapeutic areas and generate revenue


Product Use Video:



THE PROBLEM


Assessing the blood flow for surgery is challenging and costly

1. A top challenge surgeons face is knowing whether a procedure has poor blood flow.

The number one problem surgeons face is knowing whether a procedure has poor blood flow. 20% of bypass grafts have less than 
50% of average blood flow and 14% of breast reconstruction have necrosis. These cases add up: it costs around $100k per case to address breast tissue necrosis.


Source | Source



2. Current tools require contact and have challenges.






THE SOLUTION


Know-the-flow in real-time with VU-FLOW

Case studies have shown visualizing blood flow during surgeries can substantially assist in predicting if poor outcomes may occur. Poor outcomes result in longer recovery for people, costly complications, re-admissions, re-operations, or death.We designed VUFLOW to be the first non-contact visualization tool. Surgeons can now point-n-image to visualize blood flow.

*Computer generated animation for optional robotic upgrade in 2022




Business Model

Software as a Service will be offered on a pay-per-case basis and a multi-year subscription will be offered at a discount, which can be used to help capitalize sales growth. The data acquisition hardware will undergo periodic upgrades to keep up with new visualization features.


The cost for the first 7 units have been paid. We plan to fund operations through raising capital, selling subscriptions, and leveraging credit facilities through financial services in the MedTech industry. 


*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.


We plan to grow based on net income, use credit facilities to cover costs over the 4 month gap from building units to selling subscriptions.


First 2 rows indicate capability to assess blood flow speeds. The last 3 rows indicate safety elements.









THE MARKET


300 million major surgeries are being performed annually

Doctors use contact devices to measure blood flow speeds in over 300,000 cases per year. However, an average of 300 million major procedures are performed annually. The global market is estimated to be over $500M in annual sales.


A market comp Novadaq sold fluorescent angiography devices and was acquired by Stryker for $701M, 7 years after its market cap was approximately $100M on NASDAQ.


*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.


OUR TRACTION


Scheduling clinical studies

Scinovia is an FDA registered manufacturer. Several VU-FLOW units are being scheduled for comparative clinical studies in early 2022. This represents an opportunity for VUFLOW to be published, become known among the societies and conferences, and to assess various indications for potential regulatory clearance.


Surgeons from diverse therapies, e.g., bypass, vascular, plastics, cancer, and emergency rooms have shown strong interest in exploring ways that VUFLOW could help in various procedures.


*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.


Scinovia is currently integrating a robotic assisted option that will auto-adjust imaging to reduce glare and improve precision and ease-of-use.


*The above is a rendering of a future product. Product is still currently under development not yet available on the market.


WHY INVEST


Join a game-changing company

We aim to innovate and provide doctors with better tools to improve outcomes for loved ones. We’re targeting existing users of contact devices to switch to our revolutionary non-contact VUFLOW. Last year, hospitals spent over $500M on contact devices.


Our goal is for VUFLOW, which is a platform technology, to become an appliance that is used across many types of procedures.


*The above is a rendering of a future product. Product is still currently under development not yet available on the market.


Emoticons

ABOUT

HEADQUARTERS

8801 Fast Park Dr, STE 301
Raleigh, NC 27617
VALUATION

$89.29M

Scinovia’s mission is to produce state-of-the-art diagnostics to help doctors make more data-driven decisions during procedures to save more lives. Scinovia developed VUFLOW, the future of non-contact imaging diagnostics for blood flow during surgery.

TEAM

Jim Sund, PhD, MBA
Jim Sund, PhD, MBA
CEO and Founder

Jim led the development and commercialization of a life science informatics platform that was licensed by Merck & Roche. He evaluated the commercial viability of hundreds inventions for NASA and universities. Jim mentored dozens of Duke graduate consulting practicums to solve challenges for Fortune clients. As part of Lockheed Martin, Jim managed contracts, systems engineering, and computer security for the US EPA National Computing Center.

PhD - Electrical & Computer Engineering, Duke University

MBA - Duke University

BS - Chemistry, University of Florida.

BS - Biology, University of Florida

Dr. Randall Wolf
Dr. Randall Wolf
Surgeon Advisor

* Reknowned heart surgeon with over 40 years of experience performing heart bypass procedures

* first heart bypass using DaVinci robot

* Professor & Heart Surgeon, Houston Methodist

* Inventor of Wolf Mini Maze for A-fib

* Master Magician

Randall K. Wolf, M.D., is a leading innovator in minimally invasive treatment of atrial fibrillation. The first North American heart surgeon to perform robotic assisted coronary bypass, Dr. Wolf has pioneered DaVinci cardiac surgery and a number of other cardiothoracic procedures including the Wolf Minimaze, endoscopic first rib resection and endoscopic thoracic spine surgery.

Dr. Wolf has authored over 100 peer reviewed articles and book chapters. He has served as president of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) and president of the 21st Century Cardiothoracic Surgery Society. He has also served as Professor of Surgery at Ohio State University; Professor of Surgery and Biomedical Engineering at the University of Cincinnati; and Visiting Professor at The University of Texas.

BA - Indiana University

MD - Indiana University School of Medicine

Jeff Haag
Jeff Haag
VP of Engineering

Jeff was a Founding Investor who brings over 30 years of experience in Embedded Real-Time Hardware and Software Development and Software Systems Architecture across a wide range of commercial platforms with millions of users. He has participated in all levels of Software Development, from coding to architecture, from managing small teams of developers to working with and managing complex architectures across Business Units. Jeff has a very strong background in all aspects of Production Delivery of quality hardware and software products from his career spanning several years at IBM, SquareD, and 3Com, as well as 20 years at Cisco Systems.

He brings a very complete background of software systems with deep expertise in Device Management, Real-Time processing, Networking, Security, and Virtualization, wide general knowledge of mechanical and electrical engineering, as well as extensive experience managing technical customer relationships. 

MS Computer Science, North Carolina State University

BS Electrical Engineering, Virginia Tech

Dr. Kim Steinmann
Dr. Kim Steinmann
Medical Advisor

* Pediatric Hematologist/Oncologist

* Pediatric Emergency Medicine

Kim is board certified in both Pediatric Emergency Medicine and Pediatric Hematology/Oncology. She received her M.D. from the St. Louis University School of Medicine and completed her Pediatric ER residency training at Cardinal Glennon Children’s Hospital in St. Louis. She then completed her Pediatric Hematology/Oncology fellowship at University of Michigan in Ann Arbor, Michigan.

She brings extensive academic, teaching, and clinical experience from her 10+ years as a faculty/staff member at several institutions as well as 10+ years of industry experience, working on both solid and hematological malignancies with early to late phase clinical development of targeted therapies.  

Kim is a board member of the pediatric collaborative team. She has had publications in several peer reviewed journals and has presented scientific data at various national and international conferences and training events in oncology and emergency medicine.

 M.D., FCCP, FASCO

TERMS

Scinovia
Overview
PRICE PER SHARE
$2.85
DEADLINE
Jun 30, 2022
VALUATION
$89.29M
AMOUNT RAISED
$112,512.53
Breakdown
MIN INVESTMENT
$228.00
MAX INVESTMENT
$106,997.55
MIN NUMBER OF SHARES OFFERED
3,507
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Class C Nonvoting Common Stock
MAX NUMBER OF SHARES OFFERED
375,438

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Scinovia Corp.

Corporate Address

:

8801 Fast Park Dr, STE 301, Raleigh, NC 27617

Offering Minimum

:

$9,997.80

Offering Maximum

:

$1,069,998.30

Minimum Investment Amount

(per investor)

:

$498.75











Terms


Offering Type

:

Equity

Security Name

:

Class C Nonvoting Common Stock

Minimum Number of Shares Offered

:

3,508

Maximum Number of Shares Offered

:

375,438

Price per Share

:

$2.85

Pre-Money Valuation

:

$89,293,381.35











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based:

Friends & Family Early Birds Bonus:

Invest within the first 72 hours and receive 20% bonus shares

Super Early Bird Bonus

Invest within the next 72 hours and receive 15% bonus shares

Early Bird Bonus

Invest within the next 7 days and receive 12% bonus shares

Amount-Based:

Invest $1,500+: Receive 15% bonus shares

Invest $5,000+: Receive 20% bonus shares

Invest $25,000+: Receive 25% bonus shares

Invest $50,000+: Receive 30% bonus shares

Invest $100,000+: Receive 40% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Scinovia Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class C Nonvoting Common Stock at $2.85 / share, you will receive 110 shares of Class C Nonvoting Common Stock, meaning you'll own 110 shares for $285. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”. Vendor payments.

PRESS

Article Image
NC Business News Wire

Start-up Scinovia looking to change how blood flow is measured during surgery

Article Image
WRAL TechWire

Durham startup aims to raise $6M for blood-flow monitoring system

Article Image
Inkwood Research

CEO OF SCINOVIA’S TAKE ON THE BLOOD FLOW MEASUREMENT DEVICES MARKET

Article Image
North Carolina Biotechnology Center

Scinovia Developing Blood-flow Imaging System for Heart Bypass Surgeries

ALL UPDATES

06.29.22

10 Hours Left to Invest Through StartEngine!


Last Day to Invest Through StartEngine



06.29.22

Last Day to Invest Through StartEngine!

15 Hours Left to Invest Through StartEngine!

Invest Now



06.29.22

1 Day Left to Invest in Scinovia's StartEngine Campaign!

Scinovia's StartEngine Campaign Is

Closing in 1 Day!

Invest


06.28.22

1 Day Left to Invest in Scinovia on StartEngine!

One day left to invest on StartEngine!

Invest Today


06.27.22

Scinovia's StartEngine Campaign Closes in 2 Days!

Time is running out!

Don't miss the opportunity to invest in Scinovia on StartEngine



06.26.22

Scinovia's StartEngine Campaign Closes In 3 Days!


Robotic arm in positioning mode


Invest Now


06.25.22

Scinovia's StartEngine Campaign Closes In 4 Days!

VUFLOW's real-time augmented reality visualization of blood flow 

Invest now!


06.24.22

Scinovia's StartEngine Campaign Closes In 5 Days!

Our unique and effortless touch to return feature in action

Invest Now!



06.23.22

Scinovia's StartEngine Campaign Closes In 6 Days!

Become a part of advancing the future of surgical technology and invest in Scinovia today


With only six more days left of our StartEngine Campaign, we hope you'll consider joining us on this journey!

06.22.22

Scinovia's SE Campaign Closing In a Week!

Scinovia's StartEngine Campaign Closing in 7 Days!

Surgical Team Testing Robotics Integration

Invest Today


REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Scinovia.

$498.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,500.00

$1,500+ Tier

Invest $1,500+ and receive 15% bonus shares

$5,000.00

$5,000+ Tier

Invest $5,000+ and receive 20% bonus shares

$25,000.00

$25,000+ Tier

Invest $25,000+ and receive 25% bonus shares

$50,000.00

$50,000+ Tier

Invest $50,000+ and receive 30% bonus shares

$100,000.00

$100,000+ Tier

Invest $100,000+ and receive 40% bonus shares

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$112,512.53
INVESTORS
78
MIN INVEST
$228.00
VALUATION
$89.29M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.